OBI Pharma, Inc.

Taipei Exchange 4174.TWO

OBI Pharma, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 328.36

OBI Pharma, Inc. Price to Sales Ratio (P/S) is 328.36 on January 14, 2025, a -22.78% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

OBI Pharma, Inc. 52-week high Price to Sales Ratio (P/S) is 553.07 on August 29, 2024, which is 68.43% above the current Price to Sales Ratio (P/S).
OBI Pharma, Inc. 52-week low Price to Sales Ratio (P/S) is 323.28 on January 13, 2025, which is -1.55% below the current Price to Sales Ratio (P/S).
OBI Pharma, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 393.62.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Taipei Exchange: 4174.TWO

OBI Pharma, Inc.

CEO	Dr. Heidi Wang Ph.D.
IPO Date	Dec. 12, 2012
Location	Taiwan
Headquarters	No. 3, Park Street
Employees	260
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years